Qiagen N.V. (QGEN) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Qiagen N.V. (NASDAQ:QGEN) announced its earnings results on Thursday. The company reported $0.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.02, MarketWatch Earnings reports. Qiagen N.V. had a net margin of 6.02% and a return on equity of 10.46%. The company had revenue of $349 million for the quarter, compared to analysts’ expectations of $353.09 million. During the same period last year, the firm earned $0.24 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Qiagen N.V. updated its FY17 guidance to $1.25-1.27 EPS.
Shares of Qiagen N.V. (NASDAQ:QGEN) traded down 0.64% during trading on Thursday, hitting $34.09. 614,276 shares of the stock were exchanged. The stock’s 50 day moving average price is $34.08 and its 200 day moving average price is $30.91. Qiagen N.V. has a 52 week low of $24.04 and a 52 week high of $35.26. The firm has a market capitalization of $7.76 billion, a price-to-earnings ratio of 94.69 and a beta of 1.15.
QGEN has been the topic of several recent research reports. TheStreet cut shares of Qiagen N.V. from a “b-” rating to a “c” rating in a report on Monday, April 24th. Zacks Investment Research cut shares of Qiagen N.V. from a “hold” rating to a “sell” rating in a research note on Wednesday, April 5th. Deutsche Bank AG reissued a “buy” rating on shares of Qiagen N.V. in a research note on Tuesday, May 2nd. Barclays PLC reissued a “buy” rating and issued a $33.00 price objective on shares of Qiagen N.V. in a research note on Monday, May 15th. Finally, Commerzbank Ag reissued a “buy” rating on shares of Qiagen N.V. in a research note on Friday, June 23rd. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Qiagen N.V. has a consensus rating of “Buy” and a consensus price target of $32.81.
Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in shares of Qiagen N.V. by 8,793.4% in the first quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock valued at $227,114,000 after buying an additional 7,751,485 shares during the last quarter. Frontier Capital Management Co. LLC boosted its stake in shares of Qiagen N.V. by 43.7% in the first quarter. Frontier Capital Management Co. LLC now owns 2,449,006 shares of the company’s stock valued at $70,948,000 after buying an additional 744,890 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Qiagen N.V. by 2,651.3% in the first quarter. Legal & General Group Plc now owns 1,896,813 shares of the company’s stock valued at $16,690,000 after buying an additional 1,827,871 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Qiagen N.V. during the first quarter valued at $46,480,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Qiagen N.V. by 182.9% in the first quarter. Renaissance Technologies LLC now owns 1,514,898 shares of the company’s stock valued at $43,890,000 after buying an additional 979,498 shares during the last quarter. 61.02% of the stock is currently owned by institutional investors.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.